Danish-based Genmab A/S is at the forefront of developing antibody therapeutics for cancer and other diseases. Its product line includes DARZALEX, a human monoclonal antibody for the treatment of multiple myeloma, and products like teprotumumab and ofatumurnab, which are designed to address thyroid eye disease and chronic lymphocytic leukemia, respectively. The company has also developed Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. In addition to these products, there are several others in the pipeline such as Teclistamab, Camidanlumab tesirine, JNJ-64007957, and PRV-015. Genmab A/S has collaborations with notable biotech firms including Seagen Inc., argenx, and AbbVie, among others, in its efforts to discover and commercialize novel therapeutic antibodies. With its significant presence in the antibody therapeutics market, the company is poised to make a significant impact in the life sciences industry.
Genmab's ticker is GMAB
The company's shares trade on the NASDAQ stock exchange
They are based in Copenhagen, Denmark
There are 501-1000 employees working at Genmab
It is genmab.com/who-we-are
Genmab is in the Healthcare sector
Genmab is in the Biotechnology industry
The following five companies are Genmab's industry peers:
- CollPlant Biotechnologies Ltd.